# Subcutaneous Sarilumab vs Placebo in Hospitalized Patients With Respiratory Distress Caused by COVID 19

> **NCT07196306** · PHASE2 · WITHDRAWN · sponsor: **BayCare Health System**

## Conditions studied

- COVID
- COVID-19
- Corona Virus Infection

## Interventions

- **DRUG:** Sarilumab 200 MG/1.14 ML Subcutaneous Solution
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07196306
- **Lead sponsor:** BayCare Health System
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2020-05-07
- **Primary completion:** 2020-08-31
- **Final completion:** 2020-10-15
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** no participants enrolled
- **Last updated:** 2025-09-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07196306

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07196306, "Subcutaneous Sarilumab vs Placebo in Hospitalized Patients With Respiratory Distress Caused by COVID 19". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07196306. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*